Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

October 31, 2016

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

DRUG

Placebo (for Dupilumab)

Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

OTHER

Topical Corticosteroid (TCS)

All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.

Trial Locations (148)

Unknown

Phoenix

Hot Springs

Little Rock

Encinitas

Oceanside

Palmdale

San Diego

New Haven

Trumbull

Edgewater

Lake Worth

Miami Lakes

Orlando

Tampa

Alpharetta

Columbus

Savannah

West Dundee

Carmel

New Albany

Rockville

Ann Arbor

Bay City

Edina

Fridley

St Louis

Omaha

Henderson

Verona

Albuquerque

Corning

New York

Smithtown

Stony Brook

Cincinnati

Norman

Oklahoma City

Lake Oswego

Portland

Exton

Hazleton

Philadelphia

Austin

Dallas

West Jordan

South Burlington

Henrico

Norfolk

Richmond

Spokane

Phillip

Kogarah

Benowa

Dulwich

Hectorville

Carlton

Surrey

Vancouver

Ajax

Barrie

Hamilton

Markham

North Bay

Oakville

Ottawa

Peterborough

Richmond Hill

Toronto

Waterloo

Windsor

Drummondville

Québec

Hradec Králové

Náchod

Prague

Svitavy

Ústí nad Labem

Orosháza

Szolnok

Veszprém

Budapest

Ancona

Bologna

Brescia

Novara

Pavia

Perugia

Roma

Kitakyushu

Amagasaki

Yokohama

Kamimashiki-gun

Saitama-shi

Yaizu

Koto-ku

Setagaya-ku

Adachi-ku

Chiyoda-ku

Nakano

Nerima-ku

Shibuya-ku

Shinagawa-ku

Shinjuku-ku

Suginami-ku

Fukuoka

Breda

Amsterdam

Rotterdam

Groningen

Utrecht

Dunedin

Auckland

Poznan

Krakow

Wroclaw

Lublin

Warsaw

Strzelce Opolskie

Iwonicz-Zdrój

Bialystok

Gdansk

Katowice

Szczecin

Gdynia

Lodz

Skarżysko-Kamienna

Brasov

Bucharest

Cluj-Napoca

Craiova

Târgu Mureş

Bucheon-si

Suwon

Seoul

Seodaemun-gu

Uijeongbu-si

Barcelona

Alicante

Madrid

Dundee

Edgbaston

Glasgow

Sidcup

Northwood

Liverpool

Manchester

Reading

Salford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY